Antibody-Drug Conjugates and Immunotoxins

1. Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins
Pamela A. Trail

2. Antibody–Drug Conjugate Development
Aakanksha Khandelwal, Haleh Saber, Marjorie A. Shapiro, Hong Zhao

3. Assay Methodologies and Challenges
Katherine R. Kozak, Helga Raab

4. Clinical Pharmacology Strategies in the Development of Antibody–Drug Conjugates
Sandhya Girish, Manish Gupta

5. Predictive Biomarkers for Antibody–Drug Conjugates
David Dornan, Jeff Settleman

6. Factors Involved in the Design of Cytotoxic Payloads for Antibody–Drug Conjugates
Wayne C. Widdison, Ravi V. J. Chari

7. Linker Technology and Impact of Linker Design on ADC Properties
Victor S. Goldmacher, Rajeeva Singh, Thomas Chittenden, Yelena Kovtun

8. Antibody–Drug Conjugates for the Treatment of B-Cell Malignancies
Andrew G. Polson

9. Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies
John M. Lambert, Veronique Blanc, Nathalie Bail, Anne Bousseau

10. Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies
Andres Forero, Christos Vaklavas, Albert F. LoBuglio

11. Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer
Hope S. Rugo, Ian E. Krop, Yu-Waye Chu

12. CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE)
Christos Vaklavas, Albert F. LoBuglio, Mansoor Saleh, Michael Yelin, Andres Forero

13. Case Study: An Antibody–Drug Conjugate Targeting MUC16 for Ovarian Cancer
Douglas Leipold, William G. Mallet

14. EphA2 Immunoconjugate
Zhan Xiao, Dowdy Jackson, David A. Tice

15. Anti-PSMA Antibody-Drug Conjugates and Immunotoxins
Philipp Wolf

16. Targeting CD56 (NCAM)-Expressing Neoplasms with Lorvotuzumab Mertansine
John M. Lambert, James O’Leary, Kathleen R. Whiteman, Victor S. Goldmacher

17. Studies on the Metabolism of Antibody–Drug Conjugates
Xiuxia Sun, Hans Erickson

18. Design, Development, and Characterization of Recombinant Immunotoxins Targeting HER2/neu
Yu Cao, Michael G. Rosenblum

19. The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors
Joycelyn Entwistle, Mark Kowalski, Jennifer Brown, Jeannick Cizeau, Glen C. MacDonald

Nyckelord: Biomedicine, Cancer Research, Biomedicine general, Antibodies